{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:57:38Z","timestamp":1778108258409,"version":"3.51.4"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nBackground The cytotoxic activity of the pyridazin-3-one derivative LCS-1 was previously suggested to be due to the inhibition of superoxide dismutase 1 (SOD1). However, no direct evidence was provided that LCS-1 inhibits SOD1 within cells.<\/jats:p><jats:p>\nMethods In this study, we investigated the cytotoxic activity of LCS-1 against bloodstream forms of Trypanosoma brucei, a protozoan parasite that does not express copper\/zinc-containing SOD1, but an iron-containing superoxide dismutase (FeSOD).<\/jats:p><jats:p>\nResults At 250\u2009\u00b5M, LCS-1 did not inhibit the activity of FeSOD in cell lysates of bloodstream forms of T. brucei, confirming that the compound is a specific inhibitor of SOD1. However, LCS-1 displayed substantial trypanocidal activity with a minimum inhibitory concentration of 10\u2009\u00b5M and a half-maximal effective concentration of 1.36\u2009\u00b5M, indicating that the cytotoxic action of the compound cannot solely be due to inhibition of SOD1.<\/jats:p><jats:p>\nConclusion The results of this study is an important finding as it shows that LCS-1 has more than one cytotoxic mode of action.<\/jats:p>","DOI":"10.1055\/a-1001-2036","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T23:01:56Z","timestamp":1568242916000},"page":"57-60","source":"Crossref","is-referenced-by-count":7,"title":["Cytotoxic Activity of LCS-1 is not Only due to Inhibition of SOD1"],"prefix":"10.1055","volume":"70","author":[{"given":"Dietmar","family":"Steverding","sequence":"additional","affiliation":[{"name":"Bob Champion Research and Education Building, Norwich Medical School, University of East Anglia, Norwich, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yzobelle","family":"Barcelos","sequence":"additional","affiliation":[{"name":"Bob Champion Research and Education Building, Norwich Medical School, University of East Anglia, Norwich, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,9,11]]},"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1001-2036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T23:34:24Z","timestamp":1578094464000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1001-2036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":0,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2020,1,3]]},"published-print":{"date-parts":[[2020,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1001-2036","relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]}}}